financetom
Business
financetom
/
Business
/
Elf Beauty lifts annual forecasts as cosmetic, skincare demand holds up
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Elf Beauty lifts annual forecasts as cosmetic, skincare demand holds up
Aug 8, 2024 1:31 PM

By Granth Vanaik

(Reuters) - Elf Beauty ( ELF ) raised annual sales and profit forecasts after topping first-quarter estimates on Thursday, as more customers visited stores and websites to buy its affordable cosmetics and skincare products.

Beauty company Elf, like its peers in the segment, has sustained the post-pandemic boom in demand, as low-cost products from its brands such as Naturium, Skin, and Cosmetics continue to attract customers, including those having strained budgets due to a sticky inflation.

Retailers, such as Target, which house Elf's products, have also seen sales surge for beauty products in recent months.

"We have seen consumers are getting choosier, but they're choosing Elf," CEO Tarang Amin told Reuters.

Elf's stock, however, has dropped about 14% quarter-to-date, after investors raised concerns around possibility of rising tariffs on imports of its nearly 80% finished products manufactured in China and higher ocean freight costs, among other factors.

CEO Amin said that an increase in tariffs on imports from China, if Republican presidential candidate Donald Trump comes to power, would mostly impact the company in fiscal 2026.

Earlier this year, Trump had floated the idea of imposing tariffs on China again if he wins the presidential election in November and said the rate for such tariffs could exceed 60%.

"We don't like 60% tariff just because we feel it is a tax on American consumers," Amin said, adding, the tariffs impact would be addressed by raising product prices and diversifying supply chain operations.

Elf now sees 2025 sales to be between $1.28 billion and $1.30 billion, compared to previous expectations of $1.23 billion and $1.25 billion.

It now expects annual adjusted per-share profit to be between $3.36 and $3.41, versus prior projections of $3.20 and $3.25.

Net sales rose 50% to $324.5 million in the quarter ended June 30, beating estimates of about $304.7 million. Adjusted profit of $1.10 per share also topped LSEG expectations of 84 cents.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blue Sky Uranium In New JV to Advance Ivana Uranium-Vanadium Deposit in Argentina
Blue Sky Uranium In New JV to Advance Ivana Uranium-Vanadium Deposit in Argentina
Mar 26, 2025
08:41 AM EDT, 03/26/2025 (MT Newswires) -- Blue Sky Uranium ( BKUCF ) said Wednesday that it established the Ivana Minerales joint venture with Abatare Spain to advance the Ivana uranium-vanadium deposit in Argentina. According to a statement, the JV is currently vetting engineering groups to support the planned prefeasibility/feasibility study for the Ivana deposit. It is also initiating an...
Innergex Renewable Energy Says Hawaii Project Now Operational; Provides Update On Going Private
Innergex Renewable Energy Says Hawaii Project Now Operational; Provides Update On Going Private
Mar 26, 2025
08:37 AM EDT, 03/26/2025 (MT Newswires) -- Innergex Renewable Energy ( INGXF ) on Wednesday said its Hale Kuawehi Solar and Battery Storage Project on Hawaii Island reached commercial operations on March 25. The project integrates 30 MW of solar photovoltaic capacity with 30 MW/120 MWh (four hours) of battery storage, ensuring a stable and reliable supply of clean electricity...
Intellia Therapeutics' Gene-Editing Drug Gets FDA Designation
Intellia Therapeutics' Gene-Editing Drug Gets FDA Designation
Mar 26, 2025
08:36 AM EDT, 03/26/2025 (MT Newswires) -- Intellia Therapeutics ( NTLA ) said Wednesday that the US Food and Drug Administration granted the Regenerative Medicine Advanced Therapy designation to its nex-z treatment for transthyretin amyloidosis with cardiomyopathy or ATTR-CM. The company said the CRISPR-based therapy has shown it can sharply reduce serum TTR levels with a single dose, potentially slowing...
BRIEF-Fresh Del Monte Acquires Majority Stake In Avolio, An Avocado Oil Producer, To Further Its Commitment To Specialty Ingredients
BRIEF-Fresh Del Monte Acquires Majority Stake In Avolio, An Avocado Oil Producer, To Further Its Commitment To Specialty Ingredients
Mar 26, 2025
March 26 (Reuters) - Fresh Del Monte Produce Inc ( FDP ) : * FRESH DEL MONTE ACQUIRES MAJORITY STAKE IN AVOLIO, AN AVOCADO OIL PRODUCER, TO FURTHER ITS COMMITMENT TO SPECIALTY INGREDIENTS Source text: Further company coverage: ...
Copyright 2023-2025 - www.financetom.com All Rights Reserved